SCHEMBL4649728

SCHEMBL4649728

CC(C)CNCc1cnc(Nc2cccc(C(F)(F)F)c2)cc1C(C)C

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.47
CNR2 P34972 4/20 0.45
MAPT P10636 2/20 0.44
KDM4E B2RXH2 3/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
GAA P10253 1/20 0.43
AURKA O14965 4/20 0.42
EGFR P00533 1/20 0.41
SLC2A1 P11166 1/20 0.41
IDH2 P48735 2/20 0.40
PRKDC P78527 1/20 0.40
KIF11 P52732 1/20 0.40
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4648965 0.86 CNR2 (0.48) THRBCNR2MAPTKDM4EMEN1
SCHEMBL4648684 0.84 CNR2 (0.47) CNR2MEN1KMT2AEGFR
SCHEMBL14005975 0.79 CNR2 (0.51) CNR2EGFR
SCHEMBL4648963 0.78 KDM4E (0.46) THRBCNR2MAPTKDM4EMEN1
SCHEMBL14381794 0.78 CNR2 (0.56) THRBCNR2MAPTKDM4EMEN1
SCHEMBL4649749 0.78 CNR2 (0.73) THRBCNR2MAPTPOLB
SCHEMBL4650342 0.78 CNR2 (0.45) CNR2MEN1KMT2AALDH1A1POLB
SCHEMBL14065147 0.78 THRB (0.44) THRBCNR2MAPTKDM4EMEN1
SCHEMBL5080782 0.71 CNR2 (0.77) CNR2MAPTMEN1KMT2AALDH1A1
Hydrochloric Acid SCHEMBL4649162 0.70 CNR2 (0.58) CNR2MAPTKDM4EEGFRPRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080280868-A1 Pyridine Derivatives and Their Use as Cb2 Receptor Modulators GLAXO GROUP LIMITED (GB) 2008-11-13 US disclosed
US-20080280868-A1 Pyridine Derivatives and Their Use as Cb2 Receptor Modulators GLAXO GROUP LIMITED (GB) 2008-11-13 US disclosed
US-20080280868-A1 Pyridine Derivatives and Their Use as Cb2 Receptor Modulators GLAXO GROUP LIMITED (GB) 2008-11-13 US disclosed
EP-1718613-B1 PYRIDINE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR MODULATORS GLAXO GROUP LTD (GB) 2008-09-03 EP disclosed
EP-1718613-B1 PYRIDINE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR MODULATORS GLAXO GROUP LTD (GB) 2008-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280868-A1 Pyridine Derivatives and Their Use as Cb2 Receptor Modulators CNR2, CNR1, TRPV1 THRB 1292/4885CNR2 1/4885MAPT 2546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.